Published on
January 6, 2025
- 06:00 GMT
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd orphan drug designation granted to the skeletal muscle-specific drug therapy NMD670 Under this newly granted …
Distribution channels:
Media, Advertising & PR, Technology
...
